News

This in depth feature covers bit.bio's breakthrough reprogramming approach and ability to manufacture human cells at industrial sc...

Kathryn Golden, SVP Technical Operations & Cell Manufacturing, discusses how our opti-ox technology lends itself to scale through ...

Industrialising human cell manufacturing will unleash the potential of synthetic biology for reproducible research and affordable ...

The piece covers bit.bio's breakthrough in industrialising the consistent manufacture of human cells and how this will transform h...

ioMicroglia™ is set to accelerate research and drug discovery for neurodegenerative disease.

bit.bio launches the first commercially available human iPSC-derived disease models for Parkinson’s disease that carry the PRKN R2...

The piece covers the launch of bit.bio's Custom ioDisease Model Cells at the SynBioBeta conference.

Offering will provide robust, standardised tools for research and drug discovery.